Paper32255488
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
McGovern BH and 20 others. Clin Infect Dis, 2021. Cited by 135 papers, by iCite.
Cite this record
ConductScience Library. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Papers, record 32255488. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32255488
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Clostridioides difficile | Major topic |
| Clostridium Infections | Major topic |
| Microbiota | Major topic |
| Aged | |
| Clostridioides | |
| Drugs, Investigational | |
| Female | |
| Humans | |
| Male | |
| Recurrence |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02437487 | SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 32330238 | Unexpected Results From a Phase 2 Trial of a Microbiome Therapeutic for Clostridioides difficile Infection: Lessons for the Future. | https://conductscience.org/library/papers/32330238 |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 13655060 | Statistical aspects of the analysis of data from retrospective studies of disease. | J Natl Cancer Inst | 1959 | https://conductscience.org/library/papers/13655060 | PubMed |
| 2 | 32004427 | First Case of 2019 Novel Coronavirus in the United States. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32004427 | PubMed |
| 3 | 31201853 | The perils of PCR-based diagnosis of Clostridioides difficile infections: Painful lessons from clinical trials. | Anaerobe | 2019 | https://conductscience.org/library/papers/31201853 | PubMed |
| 4 | 20089970 | Treatment with monoclonal antibodies against Clostridium difficile toxins. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20089970 | PubMed |
| 5 | 24523597 | The epidemiology of irritable bowel syndrome. | Clin Epidemiol | 2014 | https://conductscience.org/library/papers/24523597 | PubMed |
| 6 | 32053787 | Regulatory Considerations for Fecal Microbiota Transplantation Products. | Cell Host Microbe | 2020 | https://conductscience.org/library/papers/32053787 | PubMed |
| 7 | 31665575 | Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31665575 | PubMed |
| 8 | 18199029 | Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. | J Infect Dis | 2008 | https://conductscience.org/library/papers/18199029 | PubMed |
| 9 | 28220514 | Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. | Aliment Pharmacol Ther | 2017 | https://conductscience.org/library/papers/28220514 | PubMed |
| 10 | 28531908 | Methods and Reporting Studies Assessing Fecal Microbiota Transplantation: A Systematic Review. | Ann Intern Med | 2017 | https://conductscience.org/library/papers/28531908 | PubMed |
| 11 | 22688413 | Metagenomic microbial community profiling using unique clade-specific marker genes. | Nat Methods | 2012 | https://conductscience.org/library/papers/22688413 | PubMed |
| 12 | 24098459 | Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. | PLoS One | 2013 | https://conductscience.org/library/papers/24098459 | PubMed |
| 13 | 26789728 | Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. | PLoS One | 2016 | https://conductscience.org/library/papers/26789728 | PubMed |
| 14 | 26169276 | Fecal Microbiota Transplantation Eliminates Clostridium difficile in a Murine Model of Relapsing Disease. | Infect Immun | 2015 | https://conductscience.org/library/papers/26169276 | PubMed |
| 15 | 27444134 | High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection. | Aliment Pharmacol Ther | 2016 | https://conductscience.org/library/papers/27444134 | PubMed |
| 16 | 29617739 | Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. | Clin Infect Dis | 2018 | https://conductscience.org/library/papers/29617739 | PubMed |
| 17 | 30957161 | Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. | Clin Infect Dis | 2019 | https://conductscience.org/library/papers/30957161 | PubMed |
| 18 | 19060152 | Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. | J Bacteriol | 2009 | https://conductscience.org/library/papers/19060152 | PubMed |
| 19 | 26348734 | Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. | JAMA Intern Med | 2015 | https://conductscience.org/library/papers/26348734 | PubMed |
| 20 | 27548329 | Are Microbial Politics Local? | Ann Intern Med | 2016 | https://conductscience.org/library/papers/27548329 | PubMed |
Cited by95
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 135 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42657533 | Microbiome-based therapeutics for Clostridioides difficile infection: additive, subtractive, and modulatory strategies in modern clinical practice. | Gut Microbes | 2026 | https://conductscience.org/library/papers/42657533 | PubMed |
| 42419269 | Ecological and dietary strategies to constrain Clostridioides difficile. | Cell Host Microbe | 2026 | https://conductscience.org/library/papers/42419269 | PubMed |
| 42379287 | The impact of fecal microbiota transplantation on host immunity and epithelial restoration following Clostridioides difficile infection. | Anaerobe | 2026 | https://conductscience.org/library/papers/42379287 | PubMed |
| 42288685 | Transplantation of encapsulated fecal microbiota: research progress and future trends. | World J Pediatr | 2026 | https://conductscience.org/library/papers/42288685 | PubMed |
| 41853554 | Live biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infection. | Front Microbiomes | 2024 | https://conductscience.org/library/papers/41853554 | PubMed |
| 41787017 | The gut as a central hub for multi-organ crosstalk in aging. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/41787017 | PubMed |
| 41698062 | Attenuated Bacteria-Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41698062 | PubMed |
| 41684675 | Targeting vaginal dysbiosis: prospects for the application of live biotherapeutics products. | Front Microbiol | 2026 | https://conductscience.org/library/papers/41684675 | PubMed |
| 41585029 | Long-Term Follow-Up After Fecal Microbiota Transplantation via Freeze-Dried Capsules for Recurrent Clostridioides difficile Infection. | Pathog Immun | 2026 | https://conductscience.org/library/papers/41585029 | PubMed |
| 41491103 | The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. | Nat Med | 2026 | https://conductscience.org/library/papers/41491103 | PubMed |
| 41239968 | Design and application of synthetic human gut microbial communities. | Gut Microbes | 2025 | https://conductscience.org/library/papers/41239968 | PubMed |
| 41239747 | Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types. | Biotechnol Bioeng | 2026 | https://conductscience.org/library/papers/41239747 | PubMed |
| 41158525 | Mechanisms of Clostridioides difficile glucosyltransferase toxins and their roles in pathology: insights and emerging therapeutic strategies. | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/41158525 | PubMed |
| 41126356 | Improving fecal transplantation precision for enhanced maturation of intestinal function in germ-free mice through microencapsulation and probiotic intervention. | Microbiome | 2025 | https://conductscience.org/library/papers/41126356 | PubMed |
| 41039491 | Gut bacteria: protective mediators, pathogenic contributors and novel therapeutic targets in Candida albicans infections. | Gut Pathog | 2025 | https://conductscience.org/library/papers/41039491 | PubMed |
| 40861872 | What's New and What's Next in Fecal Microbiota Transplantation? | Biologics | 2025 | https://conductscience.org/library/papers/40861872 | PubMed |
| 40751372 | Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection. | J Infect Dis | 2025 | https://conductscience.org/library/papers/40751372 | PubMed |
| 40705333 | Microbiota Transplantation Among Patients Receiving Long-Term Care: The Sentinel REACT Nonrandomized Clinical Trial. | JAMA Netw Open | 2025 | https://conductscience.org/library/papers/40705333 | PubMed |
| 40689613 | Differential modulation of post-antibiotic colonization resistance to Clostridioides difficile by two probiotic Lactobacillus strains. | mBio | 2025 | https://conductscience.org/library/papers/40689613 | PubMed |
| 40643244 | Straining to define a healthy microbiome. | mSphere | 2025 | https://conductscience.org/library/papers/40643244 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32255488
GET https://conductscience.org/api/papers/v1/32255488/authors?page=2